## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: National Phase Entry of PCT/EP2004/008057

Applicant Filed

: HUMMEL et al : January 17, 2006

TC/A.U.

Examiner

: 2918-111

Docket No. Customer No.: 6449

Confirmation No.:

## INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report and copies of the references are provided herewith for Examiner's review.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 02-2135.

Respectfully submitted,

Robert B. Murray

Attorney for Applicants Registration No. 22,980

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005

Telephone: (202)783-6040

RBM/cb

IAP15 Rec'd PCT/PTO 17 JAN 2006

				IAI IS ROO OT OTT IS		
				Complete if Known		
				Application Number	New Application 5 6 4 7 8 8	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 17, 2006	
STATEMENT BY AFFLICANT			<b>V</b> 1	First Named Inventor	Hummel et al	
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet	1	of	2	Attorney Docket Number	2918-111	

			FORE	GN PATI	ENT DOCUMENTS		
Examiner Initials*				nt Kind <sup>5</sup> f <i>known)</i>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
	1.	wo	2004/035079	A1	The University of Queensland	4/29/04	
	2.	wo	90/09162 A		Abbott Lab	8/23/90	
	3.	wo	92/12168	Α	Abbott Lab	7/23/92	
	4.	wo	99/00406	700406 A The University of Queensland		1/7/99	
	5.	wo	03/033528	Α	The University of Queensland	4/24/03	
	6.	wo	03/086448	Α	Promics Pty Limited	10/23/03	
	:						
			-	_			L
Examiner Signature		·			Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent pocuments. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

JAP15 Rec'd PCT/PTO 17 JAN 2006

				Complete if Known		
				Application Number	New Application 64788	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 17, 2006	
				First Named Inventor	Hummel et al	
				Group Art Unit		
				Examiner Name		
				Confirmation No.		
Sheet	2	of	2	Attorney Docket Number	2918-111	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	7.	March et al., "Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity", MOLECULAR PHARMACOLOGY, vol. 65, no. 4, April 1, 2004, pgs. 868-879.			
	8.	Finch et al., "Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 11, June 3, 1999, pgs. 1965-1974.			
	9.	Wong et al., "Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 18, August 27, 1998, pgs. 3417-3425.			
	10.	Demartino et al., "Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 27, 1995, pgs. 15966-15969.			